ATHEROSCLEROTIC VASCULAR DISEASE: AN 'INTENTION TO TREAT'
Atherosclerosis of arterial blood vessels represents the major cause of illness, disability, and death in most of the world's industrialized countries, with numbers increasing also in developing countries (1) (2) (3) (4) . Due to the multifactorial nature of atherosclerotic vascular disease, no specific treatment is available (1, 2, 5) , and its prevention and therapy continue to pose great tasks for physicians, healthcare providers, and governments (6) . Advances in understanding, diagnosis, and treatment of vascular disease have been made possible through discoveries in pathology (7) (8) (9) , biochemistry (10), molecular biology (11) , genetics (12) , pharmacology (13, 14) , surgery (15) (16) (17) (18) (19) (20) (21) , as well as in engineering technology, which resulted in new modalities to restore blood flow in diseased blood vessels (22) (23) (24) (25) . However, because of the multiple factors causally involved in atherogenesis (1, 5) , attempts to deal with this disease had to be based on an 'intention to treat' rather than an 'intention to cure' (5) .
The concept of repairing arterial blood vessels, including the insertion of non-biological structures into the arterial lumen goes back more than 100 years and was first applied by the French surgeon and biologist Alexis Carrel, M.D. (15, 18, 24) . Carrel was awarded the Nobel Prize in Physiology or Medicine in 1912 for his work in vascular medicine, which he started as a young medical student (18) . In 1894, when French President Sadi Carnot, a physicist, was assassinated by stabbing with a knife in the abdomen, bleeding to death, Carrel argued that President Carnot could have been saved if surgeons had been able to repair injured blood vessels (18) . Andreas Grüntzig's intention and approach were similar to those of Carrel, namely to repair injured blood vessels. However, for Grüntzig's approach injury originated from inside the vessel, and it was the luminal obstruction caused by atherosclerotic plaque that he intended to repair (29) .
While surgical revascularization or amputation was available for peripheral artery disease, there were no routine options for patients with advanced coronary artery disease until May 9, 1967 , when René Favaloro, M.D. introduced aortocoronary bypass surgery (19) (20) (21) 25) . In the 1950s, surgical coronary endarterectomy («currettement») had been introduced. In 1958, the Swedish surgeon Åke Senning, M.D. , further refined this method, using venous patches to seal coronary arteries after removing coronary plaques by endarterectomy (30, 31) . Coronary endarterectomy, however, did not become a standard treatment because "intimal stripping" was often associated with complications, some of which also related to the surgical instruments used (32) (33) (34) (35) . Also in 1958, Senning invented the first cardiac pacemaker (36) (37) (38) . In 1961, Senning accepted the Chair of Surgery at the University of Zurich and created the first intensive care unit on the European continent (38) ; he was going to play an essential role for Grüntzig's success in the 1970s (36) (37) (38) (39) .
The first angiography of human arteries was performed on January 17, 1896 by the physicist Eduard Haschek, Ph.D. and the physician Otto Th. Lindenthal, M.D at the Physics Institute of the University of Vienna (40) . The anatomist Julius Tandler, M.D. had placed the hand of a corpse at their disposal. The arterial vessels were filled with Teichmann's solution (iodine solution), a mixture of chalk, cinnabar, and paraffin, and applying X-rays ["X-Strahlen"] with an exposure time of 57 min resulted in the first angiogram (40) . (43) and aortography (44) .
Catheterization in humans was first performed by the German physician Werner Forssmann, M.D. . In the late summer of 1929, as a surgical resident at the age of 25 years and only one year out of medical school, Forssmann performed right heart catheterization on himself using a urinary catheter at a small provincial hospital at Eberswalde (45) . He subsequently lost his job because he had disobeyed orders of the Department Chair (45) (46) (47) . For these most daring self-experiments, published by Forssmann between 1929 and 1931 (45, 48, 49) , he was awarded the Nobel Prize in Medicine in Physiology or Medicine in 1956 having pioneered cardiac catheterization (50) . Forssmann (47, 50) .
Roughly a decade after Forssmann had performed the first human cardiac catheterization (Andreas Grüntzig had just been born), the Cuban radiologist Pedro L. Fariñas, M.D. (1892-1951) developed a catheter-based technique for arteriography of the aorta by introducing an urethral catheter through an exposed femoral artery, the results of which he published in 1941 during the Second World War (51, 52) . However, Fariñas' method required surgery.
Yet another decade later, a young resident at Karolinska Institutet in Stockholm by the name of Sven-Ivar Seldinger, M.D. was working on his doctorate thesis at the Department of Radiology, trying to optimize the insertion of arterial catheters into punctured arterial blood vessels. Seldinger found that -inserting first a guide wire through the needle lumen into the artery, then withdrawing the needle and subsequently inserting a catheter of the same size as the needle via the guide wire -was a fast, safe, and feasible method for arterial catheterization. He published his new method, still known and used today as the Seldinger technique, in 1953 (53) . Ironically, his Department Chair deemed this new approach to be insufficient for awarding Seldinger his doctorate (54) .
On October 30, 1958 , F. Mason Sones, M.D. at the Cleveland Clinic inadvertently performed the first angiography of a right coronary artery in a 26-year-old patient, establishing coronary angiography as a diagnostic tool and for future developments associated with it (55, 56) . He first reported more than 50 cases at the American Heart Association's Scientific Sessions in 1959 (57) . At about the same time, the young surgeon Thomas J. Fogarty, M.D. (born 1934), developed a balloon catheter for removing emboli and thrombi from peripheral arteries (58) . Fogarty published the concept for his embolectomy balloon catheter in 1963 (59) . The catheter was inserted by surgical arteriotomy, forwarded through and behind the clot, the balloon inflated, and the clot extracted (58) . For over a decade, all catheters were hand-made by Fogarty (an example that Grüntzig later would follow) before becoming commercially available in 1969.
1964: CHARLES T. DOTTER AND PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY
Catheter-based percutaneous treatment of occlusive arterial disease had its origins with Charles T. Dotter, M.D. (1920 Dotter, M.D. ( -1985 in the United States (59) (60) (61) (62) (63) had joined Dotter as a radiology fellow at the age of 39 years after having spent more than a decade as a family physician (67) . Only shortly thereafter, he would introduce the transfemoral access for cardiac catheterization (67, 68) , which would become the standard access route for cardiac catheterization for many decades (67) . Six months after his lecture in Karlovy Vary, Dotter and his trainee Judkins performed the first intentional transluminal angioplasty: the patient Dotter had selected was an 83-year-old lady by the name of Laura Shaw (Figure 2) (60, 63, 67, 69) , bedridden for months with a cold, painful left leg, and admitted for amputation due to progressive gangrene. A poor run-off arteriogram and the patient's general condition were thought to contraindicate reconstructive surgery and the patient also refused surgical amputation of her foot (70) . After diagnostic angiography on January 6, 1964 had revealed a tight stenosis of the distal superficial artery (60), on January 16, 1964 at 2 p.m., a co-axial catheter system (consisting of a tapered 8 and 12 Fr Teflon® catheter) was introduced to dilate the stenotic area (Figure 2) (60) . The angioplasty procedure was successful, the gangrene healed, and the artery remained open until the patient's death from heart failure 3 years later. Dotter's handwritten notes on the first percutaneous transluminal angioplasty (PTA) procedure and the typed report are shown in Figure 3 .
Dotter published the results of the first patient cases together with Judkins in the same year, and in their article specified further the possible future use of his new method in coronary and renal arteries, at the time applied only to peripheral arteries. (60) Importantly, in his article Dotter already describes in detail the concept of an expandable (dilator/balloon) catheter ("hydraulic dilatation"), which he was developing at the time (60). Dotter mentioned to his patients that he was working on this new catheter, and one patient also reported in his article is quoted that he "anxiously awaits the development of the dilating catheterprobe" (60 Finally, Dotter presents the concept later to be known as coronary stenting, which at the time he referred to as «endovascular splint», and describes re-endothelialization as "re-intimalization" as the essential regulatory role of vascular endothelial cells in atherosclerosis (8, 9, 71) (60) Only one year later, in 1965, Dotter dilated a stenosed iliac artery using an embolectomy balloon developed by Thomas J. Fogarty (72) , but concluded that the compliant balloon was not suitable for arterial dilatation and a more rigid one would be needed (64, 72) .
Already half a century ago (69), Dotter realized the educational value of film recordings (nowadays video recordings) (73) . His 1968 training movie entitled "Transluminal Angioplasty" written, directed, and narrated by Dotter himself on how to perform the angioplasty procedure has been recently released on behalf of the 50th anniversary of its introduction to medicine (69, 73) . This movie was to play an important role in the friendship that later developed between Dotter and Grüntzig and will be further discussed below. It is noteworthy that in this movie -like in his 1964 article pioneering angioplasty (60) -Dotter mentions the potential future use of percutaneous transluminal angioplasty in coronary arteries (73) . Only 7 years later, Andreas Grüntzig at the University of Zürich would succeed in performing the first experimental coronary balloon angioplasty on September 24, 1975 (74, 75) . It was Dotter's vision and his new approaches that would become an essential element for Andreas Grüntzig's future work in vascular medicine (76 
ANDREAS GRÜNTZIG: PHYSICIAN AND POST-DOCTORAL FELLOW IN HEIDELBERG AND LONDON
On April 8, 1964, Grüntzig graduated from medical school at the University of Heidelberg and two years earlier had published his first scientific article which included the data of his D.M. thesis on ventilation effects on dead space changes (79) . He wrote his thesis under the supervision of Gotthard Schettler, M.D. , one of Germany's foremost atherosclerosis researchers at the time (80 (99) . One of Grüntzig's patients asked him whether it was possible -instead of using drug treatment or undergoing complex coronary bypass operations -to just "clean" his obstructed arteries, like a plumber cleans tubes using wire brushes. Grüntzig found this idea "fascinating " (37, 96) . According to Grüntzig's own words (96) Bollinger soon recognized the exceptional professional qualities of Grüntzig, who worked into the night to help Bollinger with his research papers (99 (110) and even once used an embolectomy balloon to dilate an iliac artery (64, 72) . However, Dotter could not develop a sufficiently rigid balloon catheter. To improve angioplasty of larger arteries, Dotter in 1966 had constructed a "reinforced balloon-dilating catheter" in which a woven fiberglass sheath surrounded a simple balloon catheter (70). Grüntzig knew also of studies done with so-called caged balloon catheters («Korsett-Ballonkatheter») introduced in 1973 by Werner Porstmann, M.D. in Berlin. This catheter consisted of an 8-Fr outer Teflon® catheter with four longitudinal slits. A latex balloon catheter inflated inside the slits permitted dilation up to 9 mm, sufficient to treat iliac artery lesions, yet it did not yield the expected results (111). Dotter improved Porstmann's device and used the "caged balloon-dilating catheter" for successful treatment of iliac artery obstructions in 48 patients (112) . Early failure with thrombosis, however, limited the use of this dilating catheter and neither of these balloon catheters ever found its way into wider practice (70) . Despite unsuccessful attempts of his colleagues, Grüntzig remained optimistic and was convinced that the idea to apply defined pressure from the luminal side using an inflatable balloon to the stenosed vascular wall would be the way to make his idea work.
In Grüntzig invited Zeitler back to Zürich to introduce the"dottering" of occluded arteries (dilating arteries using the Dotter-catheter technique, or "Dottern," as the German physicians called it). In the same year, on December 15, 1971, Grüntzig began performing angioplasties using Dotter catheters in Zürich, the first of about 50 cases that would follow. Grüntzig published the results of the first Dotter angioplasty studies in Zürich in 1973 (113) .
1974: THE FIRST BALLOON ANGIOPLASTY AT THE UNIVERSITY OF ZÜRICH
According to Grüntzig (22) , the idea for the balloon catheter was born during the same time when he began to use Dotter catheters in Zürich, i.e., in late 1971. Within another 2 years after his arrival in Zürich and without any support from the federal funding agencies, working at home in the evenings and on weekends in addition to his full-time clinical duties, Grüntzig had succeeded in having functional, hand-made balloon catheters at his disposal (22) .
In Grüntzig's typed report of this first successful balloon angioplasty and the angiographs of another early femoral artery balloon dilatation performed in a 74-year-old patient a week later are shown in Figure 5 . Though Grüntzig refers to his balloon new device as"new dilatation catheter" (neuer Dilatationskatheter), he described this first balloon PTA procedure simply as "Dottern." To indicate that this was the first ever balloon dilatation, Grüntzig's assistant Maria Schlumpf in red ink at the time added to the report the word "Dilatation" (Figure 5 ) to indicate that the procedure was different from the regular Dotter-catheter procedures that Grüntzig was also routinely doing at the time. Like Dotter's first patient Laura Shaw 10 years earlier (Figure 2 ), Grüntzig's first patient Fritz Ott was soon able to walk again free of pain (99) (100) (101) .
Less than a month after the first femoral balloon angioplasty, Grüntzig performed the first balloon angioplasty of an iliac artery stenosis on March 6, 1974 using a shorter but wider balloon measuring 8 mm in diameter (the tip of the original catheter used is shown in Figure 6 ). Pre-and post-interventional angiograms of this first iliac artery dilatation were included in the initial report by Grüntzig Hopff was an expert in the chemistry of polyvinyl chloride (PVC) and an emeritus professor of organic chemistry at the Federal Institute of Technology (ETH) in Zürich. Based on the results of his research (114, 115) , he suggested to Grüntzig to use PVC as material of high rigidity that might be suitable for the use as a dilating balloon. In the manuscript of his unfinished autobiography, (22, 26) . We have recently discussed how the international recognition of this method was delayed because the article was published in German only (26) . Grüntzig initially coined his technique "percutaneous transluminal dilatation" (116) . In his habilitation thesis, submitted to the University of Zürich in 1977 and qualifying him for faculty rank, Grüntzig referred to his method as "percutaneous transluminal recanalization" (116), a term previously introduced by Dotter (60) and also used by others (117) . For the cover of his habilitation thesis, which he published as a book (116), Grüntzig selected pre-and post-interventional angiograms of a balloon catheter-treated femoral artery occlusion, which he successfully re-opened on October 27, 1975 , these angiograms are shown in Figure 7 . The Grüntzig balloon angioplasty procedure became known as PTA or as "percutaneous transluminal coronary angioplasty" (PTCA) in cardiology (118) , with reference to the terminology originally introduced by Dotter (60, 64, 73) . Grüntzig filed a patent application on the balloon catheter concept with the U.S. Patent Office on November 21, 1977 (Figure 6 ) and simultaneously with patent offices in Switzerland, Germany, France, England, and Japan (26) , securing the rights to his intellectual property of the balloon catheter principle (Figure 8) . The bottom panel of Figure 8 shows the first balloon catheter ever made by Grüntzig at a stage when it was not yet intended for patient use.
BACK INTO THE FUTURE: PERSONALIZED MEDICINE IN THE 1970s
For the next two and a half years, each balloon catheter would be custom-made for each individual patient on the Grüntzig kitchen table (Figure 9 ) (36) . Prior to the PTA procedure, Grüntzig would obtain a native angiogram, take it home, measure the arterial lumen and length and width of the stenosis from the angiogram, calculate the optimal diameter and length of the balloon needed, and build a balloon to fit that particular stenosis (39); he would accomplish this together with his assistant Maria Schlumpf and the help of their spouses, Michaela Grüntzig and Walter Schlumpf. Thus, there was «personalized medicine» already in the early 1970s.
www.frontiersin.org FIGURE 8 | Top: the Grüntzig balloon catheter principle. The double-lumen dilatation catheter (120) now contains a main lumen and an additional lumen. The main lumen allows insertion of the guide wire, pressure measurements, and injection of contrast dye. The balloon segment at the catheter tip can be positioned in the stenosed or occluded vascular segment and is filled with liquid via the additional lumen. By applying an equally distributed and constant pressure between 4 and 6 atmospheres, the atherosclerotic plaque occluding the artery is pressed against the vessel wall for 10-30 s. The maximum diameter of the inflated balloon is 4 mm for femoral arteries and 8 mm for iliac arteries. Once the balloon is deflated, the newly formed vascular lumen opens, and blood flow is restored. In its deflated form, the balloon will adhere to the catheter like an umbrella and can be pulled back, and the procedure is completed. Figure  legend and drawing according to a sketch by Andreas Grüntzig (36) . Bottom: the very first balloon catheter constructed by Grüntzig in 1971, long before balloon catheters were fully functional for the use in patients. The tip of this single-lumen catheter was sealed to allow inflation and extension of the balloon, which was glued and fixed on both sides with a thread onto the catheter tube. Balloons were fixed with surgical sutures to all hand-made catheters until mid-1975 when Cook and later the Schneider company began manufacturing Grüntzig balloon catheters. Photographs reproduced with permission of Maria Schlumpf, Zürich.
The first single-lumen balloon catheters (used until January 1975) were red "Ödmans" [catheters] , in which little holes were cut using razor blades in those portions of the catheter where the balloon was to be inflated. The PVC balloon tube was glued to the catheter and both ends were fixed with a fine thread; the knots of the threads tying the balloon tube to the catheter were always done by Grüntzig himself, who would justify this with his surgical skills being the only physician on the team (39) . All balloon catheters were used only once, and until the second half of 1976, when the Schneider company was founded and began to manufacture Grüntzig's balloon catheters, every catheter used for balloon angioplasty procedures in Zürich was a hand-made, custom-built device manufactured in the evenings and on weekends (36) (Figure 9) .
1977: THE FIRST CORONARY BALLOON ANGIOPLASTY
Soon, Grüntzig would develop a double-lumen catheter allowing greater versatility and better handling than single-lumen devices, and he commissioned engineer Helmuth Schmid to add a second groove into the red Ödman catheters (39) . The first femoral angioplasty using a double-lumen balloon catheter was performed on January 23, 1975 (119) , and Grüntzig published his experience with this new device in 1976 (120) (Figure 10) ; ironically, the article abstract does not mention the word "balloon" but only describes the new double-lumen balloon catheter as "a modification of Dotter's transluminal recanalization of stenoses and occlusions" (120). Grüntzig was now able to apply equal, constant and defined pressure to the Frontiers in Cardiovascular Medicine | Vascular Medicine FIGURE 10 | Top: A double-lumen catheter for iliac artery balloon angioplasty, connected to a three port stop-cock, with one port connected to a syringe containing liquid to inflate the distensible balloon portion of the catheter. Tape measure indicates centimeters. Bottom: Hand-made double-lumen balloon catheters assembled by Grüntzig and his associates on his kitchen table shown in Figure 9 . Shown on the left is an inflated iliac artery balloon catheter (with a similar, deflated catheter to its right) and an inflated femoral artery catheter (with a similar, deflated catheter to its right). Note that the balloons are tied to the catheters with fine surgical threads and that catheter tips have been conically tapered, which was done by hand using sandpaper. Inflated balloon diameter of femoral catheters is 4 and 8 mm in iliac artery catheters. Tape measure indicates centimeters. Photographs reproduced with permission of Maria Schlumpf, Zürich. vascular wall (Figure 8) as he had planned in 1971. While Grüntzig continued to treat patients with peripheral vascular disease using new, double-lumen balloon catheters (Figure 10) , he also started to explore other vascular territories. In 1974, Grüntzig began developing and experimenting with catheters of reduced diameter that would allow their use in coronary arteries (Figure 11) .
Grüntzig was aware that others, including Dotter -who already mentioned the coronary circulation as a potential target for angioplasty in his 1964 article (60) , had thought of a broader application of angioplasty including the coronary arteries, and specifically acknowledged Dotter's pioneering role in the field (29 Grüntzig's younger daughter Sonja, who recalls having her meals at the same kitchen table that the catheters were made on, joked about herself being a "twin" of the Grüntzig balloon catheter, as her father was completely absorbed with making his idea work (123) .
Grüntzig began to evaluate new, more refined and thinner coronary balloon catheters in canine coronary arteries (74, 121, 122) in which the surgeons had experimentally induced coronary stenoses (Figure 11) . The first balloon dilatation of a coronary artery was performed in Zürich on September 24, 1975 (119) . The data from these experiments -demonstrating the feasibility and efficacy of this approach -were presented at the Spring meeting of the Deutsche Gesellschaft für Kreislaufforschung (today Deutsche Gesellschaft für Kardiologie, DGK) in Bad Nauheim, Germany, in April 1976 (74) , as well as at the American Heart Association's Scientific Sessions in Miami, FL, USA, November 15-18, 1976 (124) (Figure 11) . Given the success of coronary balloon angioplasty in his experimental studies, Grüntzig was www.frontiersin.org FIGURE 11 | Left: Schematic representation of the coronary double-lumen balloon dilatation catheter used for PTCA procedures of stenosed canine coronary arteries, which Grüntzig published in 1976 (74, 121, 124) . The preformed guiding catheter is sealed by an adaptor against the dilatation catheter localized inside. The main channel of the double-lumen catheter is connected to a three port stop-cock, which can be used to either measure coronary pressure, to inject contrast dye, or to perfuse the coronary artery with arterialized blood. Connected to the neighboring channel of the dilatation catheter is a syringe, which is used to inflate the distensible segment of the dilatation catheter. Pressure is applied by filling the distensible segment, which exhibits only minimal compliance. To demonstrate perfusion with arterialized blood, contrast dye was injected via the main channel, resulting in visible filling of the circumflex branch of the left coronary artery. determined to test its feasibility in coronary artery disease patients (99, 116) . Only now, having successfully completed translational research that had already resulted in a new, non-surgical treatment of occluded peripheral arteries and established coronary angioplasty in experimental studies (74, 121, 122) , Grüntzig applied for research funding from the Swiss National Science Foundation (SNSF). Within the next 4 years, he was awarded three SNSF research grants as Principal Investigator (125) (126) (127) .
As the first successful renal angioplasty had been performed by Zeitler at the Aggertal-Klinik in 1970, using co-axial Dotter catheters (29, 128) , Grüntzig also began to explore this vascular territory. In Zürich, on February 2, 1977, Grüntzig for the first time inserted his balloon catheter into a stenosed human renal artery, and into a human coronary artery on February 16, 1977 ; in both cases, Grüntzig did not perform angioplasty (39) . In December 1977, Grüntzig at the University of Zürich (29) (86, 130) As the application of the new technique to human coronary arteries would be challenging and in order to allow development of the PTCA procedure in a safe manner, Grüntzig insisted PTCA to be performed during bypass surgery so that patients would not be jeopardized (131) On May 9, 1977, Grüntzig, with the assistance of Myler performed the first of a number of coronary balloon angioplasties in anesthetized patients during coronary bypass surgery (28, 133, 134) by retrograde insertion into a stenosed coronary artery after arteriotomy. Several coronary balloon angioplasties were done from the opened thorax, and all dilations were done before the surgeons established the aorto-coronary bypass (135) . Myler also visited Grüntzig in Zürich (Figure 12 ) and became a close friend (136) (137) (138) .
Four months after the first intra-operative coronary angioplasties in San Francisco, and only because Grüntzig had Senning's unreserved support (36, 38, 39) , Grüntzig successfully performed the first PTCA in Zürich in a conscious patient -38-year old Adolf Bachmann -who had been originally scheduled for bypass surgery because of an isolated LAD stenosis [reviewed in Ref. (28, 131, 133, 135, (139) (140) (141) (142) ]. The nurse assisting Grüntzig took his notes during the procedure. In his notes, the coronary artery balloon dilatation is referred to as "Coronar-Dotter" (Figure 11 ) and the balloon device as "Coronar-Dotter Kath[eter] nach Grüntzig " [Coronary Dotter catheter according to Grüntzig ] , paying tribute to Dotter who had opened this field more than a decade earlier (Figure 11) . Indeed, others (and Grüntzig himself) referred to the balloon catheter as the"Grüntzig balloon catheter" (139, (143) (144) (145) (146) , which subsequently was also utilized for intra-operative transluminal coronary angioplasty (72, 147, 148) , for dilating recoarctation of the aorta (149) , and for non-cardiovascular applications such as dilation of bronchial stenoses (150, 151) , or biliary (152) or ileocolonic strictures (153) . Interestingly, the idea of applying "angioplasty" to re-open obstructed nasolacrimal ducts had been introduced already in the 1940 (154) , and is now done using Grüntzig balloon catheters (155) (156) (157) (158) .
Grüntzig published the results of coronary balloon angioplasty as a preliminary report in the Lancet in 1978 (124) . He published the results of a larger number of patient cases together with Senning a year later (75) .
The success and acceptance of coronary balloon angioplasty in the field was by no means immediate. Grüntzig had only been able to perform the first coronary balloon angioplasty because he had the full support of Senning, who during a conference meeting at the hospital in Zürich with surgeons and internists attending cleared the way for Grüntzig with his famous quote (36, 100, 101): As a cardiac surgeon, Senning was well aware of the potential risks that might be associated with the very delicate procedure in small-lumen arteries. By April 1979, Grüntzig had treated 60 patients applying PTCA, 6 of whom had to undergo emergency bypass surgery to prevent a major myocardial infarction (some of them requiring reanimation) (29, 159) ; a small percentage of these patients experienced a myocardial infarction; however, according to Turina all these patients survived the PTCA or the surgical procedure. By April 1979, Grüntzig reported a primary success of PTCA in 41 out of 60 patients; in 8 of these patients Grüntzig performed balloon angioplasty in stenosed aorto-coronary bypass grafts (29) : at that time, PTCA had been successfully applied by Richard K. Myler Grüntzig's home institution continued to be hesitant to let him proceed with the PTCA procedure. The skepticism and resistance toward Grüntzig's new approach expressed by his superiors in Zürich, Siegenthaler and Krayenbühl (38) , is also reflected by the fact that Grüntzig had to wait for more than 2 months to have a second patient referred for this procedure after his first successful PTCA (122) . As a consequence, 65 out of the 169 patients who underwent PTCA in Zürich came from abroad [the 8th PTCA patient was an American (160)]. In fact, even for the initial report of the first PTCA cases of published in the Lancet in February 1978 (161) , two of the five reported PTCA procedures had to be done by Grüntzig at the University of Frankfurt (122) (166) . The article was followed by a press conference that was broadcasted by the Swiss national television (SRF) (28) . Less than a week after the press conference and after also local German newspapers had praised the new procedure as hope for heart disease patients, on February 13, 1978, Lichtlen wrote a personal letter to Siegenthaler, with copy to Senning and Grüntzig (39) Fortunately, time would tell that Lichtlen's concerns were not justified.
ANDREAS GRÜNTZIG: CLINICAL TEACHER AND EDUCATOR IN VASCULAR MEDICINE
Following the success of the PTCA, cardiology and vascular medicine colleagues came to Zurich hoping that Grüntzig would teach them the new method. These teaching requests became so timeconsuming that he could no longer accomplish his daily clinical routine as full-time attending physician at the cardiology division of the Medical Policlinic. Grüntzig therefore decided to start live demonstration courses at the Zurich Kantonsspital performing balloon angioplasty with patients in the catheterization laboratory (28, 36, 133) (Figures 13 and 14) . Grüntzig held four live demonstration courses in Zürich between 1978 and 1980 (167) , all attended by cardiologists and vascular physicians from around the world. During the first course held on August 7-10, 1978 , and with 28 physicians attending, Grüntzig performed 7 PTCAs, 2 femoral PTAs, and 1 renal artery PTA (39) . While the first two courses (the second counted 97 attendees) were held in the historical building of the hospital, the third and fourth course accommodating 171 and 221 attendees, respectively, were held in the newly built, large lecture hall (Grosser Hörsaal Nord, Figure 13 bottom and Figure 15 ). Grüntzig transmitted live from the catheterization laboratory discussing with the audience while being with the patient who was undergoing the angioplasty procedure. Ironically, according to Grüntzig, it was during these live demonstration courses that he learned the most from the comments and questions of his peers (36, 39) . Grüntzig enjoyed direct discussion with course attendees during breaks from the angioplasty procedures that he did in the catheterization laboratory (Figure 13) , and was considered an extraordinarily gifted teacher by his peers (76, 138, 165, 167) .
Although the PTCA method had just been introduced into clinical practice, Grüntzig did not consider this a problem and, according to his former assistant Maria Schlumpf, he was convinced of its safety when performed correctly (36) . In fact, Grüntzig was always and first and foremost concerned with the safety of the patient, and initially thought -perhaps because 1 out of 10 patients underwent emergency surgical revascularization in the early years (159) -that only 5-10% of all coronary artery disease patients might be eligible to be treated with his new method. Grüntzig summarized his experience from teaching in the early PTCA courses as follows: as an enthusiastic audience with the truth and which helped a great deal in teaching and spelling out the method» (39) Grüntzig repeatedly emphasized that avoiding complications and ensuring patient safety has utmost priority when selecting patients for coronary balloon angioplasty.
1980: LEAVING ZÜRICH
His home institution and his superiors were unwilling to provide Grüntzig with the needed support despite the overwhelming success of his new treatment (36, 119, 165 Siegenthaler, Physician-in-Chief of the Medical Policlinic went by the name of «little Napoleon» [«kleiner Napoleon»] among his staff (169) , in reference to Napoléon Bonaparte (1769-1821), who has been described as the early nineteenth century dictator of France (170) . When confronted with the situation, Siegenthaler blamed the Government of the Cantone of Zürich (Zürcher Regierungsrat) and denied any responsibility on his part, while Grüntzig kept complaining to him that patients on waiting lists for the new treatment were dying (37) . Finally, Grüntzig also personally approached Peter Wiederkehr, member of the Zürcher Regierungsrat, who also was unwilling to help (37) . Only in 2009, shortly before Siegenthaler's death (and more than 30 years after Grüntzig's first successful PTCA at the University of Zürich) Siegenthaler publically admitted that he was afraid at the time that he might have gone to prison should Grüntzig's procedure had failed (166) . In an interview, which he gave in the U.S. in the early 1980s, Grüntzig began looking for a position in Germany at the University of Tübingen, at the University of Frankfurt, and at the University of Düsseldorf, but without success. However, institutions in the United States indicated that they would provide him with the needed support that would allow him to further refine and advance the PTCA method and to treat larger numbers of patients. Several institutions, among them Harvard University and the Cleveland Clinic, offered Grüntzig positions and he finally accepted an offer from Emory University in Atlanta, GA, USA (131, 135) . Unlike Switzerland, the United States immediately realized Grüntzig's capacity and potential to advance cardiovascular medicine.
www.frontiersin.org Grüntzig was classified as a "national treasure" by the authorities in 1980 (172); however, he was never granted United States citizenship (96) . Emory University had just received a donation of 105 million USD from the Coca-Cola Foundation (an amount which in 2014 would equal approximately 250 million USD), one of the biggest research grants ever given to an academic institution (99) , which allowed the hospital to expand on treatment of coronary artery disease using balloon angioplasty technology. Grüntzig accepted a Professorship at Emory University Medical School, with the understanding to serve as the Director of Interventional Cardiovascular Medicine at Emory (119) . After his death, to honor and acknowledge Grüntzig's contributions and pioneering work in the field, Emory University established the «Andreas Gruentzig Cardiovascular Center» to further build upon Dr. Gruentzig's progress in the area of interventional cardiology (96, 173) .
Twenty-five years after Grüntzig had died and only shortly before his own death, Siegenthaler for the first time publically claimed that "Grüntzig had lost sight of his boundaries," that he had become "rich and world-famous" in Atlanta, GA, USA, and spread the idle rumor that fame and success had gotten to Grüntzig's head (166) . At the same time, Siegenthaler continued to credit and portrait himself as the scientific midwife of balloon angioplasty in books, articles, and on internet websites. Notably, Siegenthaler listed Grüntzig's article on coronary angioplasty published in the New England Journal of Medicine (75) among his own most important publications («Die wichtigsten Publikationen Walter Siegenthalers») (166) .
At the last live demonstration course in Zürich in early August of 1980, Dotter received a ring from Grüntzig as a token of appreciation for his achievements in the field of cardiovascular medicine (Figure 15) . Upon his return to Oregon -Grüntzig had already decided to leave the University of Zürich -Dotter, on August 22, 1980 , in a personal letter (39) 
Charles T. Dotter»
Today, Dotter's sentimental gift to Grüntzig is publicly available (73) .
At Emory, Grüntzig had only 5 years left to continue teaching and educating fellows and medical colleagues and continued the angioplasty demonstration courses which he had started in Zürich. Between 1980 and 1985, Grüntzig organized 10 courses for his colleagues who came to Emory from all over the world to receive his advice (167) (Figures 9 and 12) (Figure 16) . Only a few months before Grüntzig's death, Milt Freudenheim, a journalist with The New York Times, outlined the financial expectations associated with the predicted growth of coronary angioplasty in cardiovascular medicine; he also described how Grüntzig's intellectual property of the balloon catheter concept could not be secured by the company who first manufactured the Grüntzig balloon catheter in Switzerland and was soon sold to a larger company (175) .
Shortly thereafter, Grüntzig gave his last interview at Emory with Burt Cohen [available online (176) (28, 177) . The investigation of the crash that immediately followed Grüntzig's tragic and early death has not been conclusive. After 30 years, several questions remain unresolved to this day (28, 177) .
TRANSLUMINAL BALLOON ANGIOPLASTY: 40 YEARS ON
Building on Dotter's initial idea that was based on an accidental observation (63, 64, 70) , the use of balloon catheters introduced by Grüntzig to restore blood flow in stenosed peripheral and coronary arteries has developed into one of the most successful therapeutic interventions of all time. As demonstrated by Carrel in animal experiments a century ago (15) , it was again Dotter who already in 1964 developed the concept of endovascular «splints» and who proposed to use endovascular stents as non-biological structures to improve the stability of the diseased arterial wall (60, 178) (Figure 17) . Dotter, Rösch, and colleagues were also the first to use a refined mode of application after balloon angioplasty had been invented and introduced the word "stent" to vascular medicine and for the treatment of peripheral arteries (179, 180) . The first coronary stent, initially designated "coronary endo-prosthesis," was deployed by Jacques Puel, M.D. at the University Hospital in Toulouse, France, on March 26, 1986 (180, 181) (Figure 17 ) also made important contributions (182) (183) (184) (185) .
Forty years after its introduction, balloon angioplasty continues to save lives of patients with acute myocardial infarction (131, 135, 140, 142) . Balloon angioplasty saved patients from disability by preventing leg amputations, as demonstrated by both Dotter and Grüntzig with their very first patients (22, 60) . The discovery of balloon angioplasty represents perhaps one of the best early examples of translational medicine in recent medical history (26, 140) . What Dotter as early as 1964 in his first article (60) and 1968 in his film (73) envisioned to be applied in patients with coronary artery disease some day, Grüntzig translated into clinical application within a little more than a decade (26, 75, 161) .
Coinciding with the 40 th anniversary of the first balloon angioplasty in peripheral artery disease at the University of Zürich, the U.S. FDA approved the first drug-coated balloon for peripheral vascular interventions on October 12, 2014 (186) , and corresponding results were recently published by Jaff and associates (187) . Future applications of balloon angioplasty in humans may also include the combination of adjuvant drug treatment targeting disease mediators (6, 188) .
In 2013, Grüntzig was posthumously awarded the «TCT Career Achievement Award» for founding the field of interventional cardiology (189) . Although Grüntzig foresaw the developments of balloon catheter application in many ways (in the 1980s, Frontiers in Cardiovascular Medicine | Vascular Medicine he expressed his interest in performing PTAs of extracranial arteries -which has become clinical practice today), Grüntzig's clinical interests were by no means limited to interventional cardiology. In fact, he had received extensive training in public health and disease prevention and in the last years of his life also developed a keen interest in preventive cardiology, a field, which also would see major developments in recent decades (6, 190) .
ANDREAS GRÜNTZIG: THE HUMAN BEING
On June 25, 2014, Andreas Grüntzig would have celebrated his 75th birthday. It is most obvious that in his professional life as a physician and as a scientist Grüntzig -in many ways -succeeded in achieving more in half a lifetime than most of us ever will. He did persevere against all obstacles that he was confronted with, both in Germany and in Switzerland, with enormous will power, optimism, intellect, hard work, and after all -remaining the same person, "a real Mensch" that he had been since the early days. 
